Samalizumab

DRUG2 trials

Sponsors

Alexion Pharmaceuticals, Inc.

Conditions

Advanced Solid TumorsB-cell Chronic Lymphocytic LeukemiaMultiple Myeloma

Phase 1

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

TerminatedNCT00648739

Alexion Pharmaceuticals, Inc.B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma

Start: 2008-06-19End: 2010-12-14Updated: 2019-03-05

Study of Samalizumab in Patients With Advanced Cancer

TerminatedNCT02987504

Alexion Pharmaceuticals, Inc.Advanced Solid Tumors

Start: 2016-11-17End: 2017-09-27Updated: 2018-07-18

Related Papers

Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Journal for ImmunoTherapy of Cancer2019-08-2381 citations